| Website | zosanopharma.com |
| Category | BioTech |
| Phone | 510-745-1200 |
| Employees | |
| Founded | 10/06 |
| Description | Osteoporosis Treatment Research |
| TOTAL | $120M |
| FUNDING TOTAL | $120M |
| Series A, 11/07 New Enterprise Associates Nomura Phase4 Ventures HBM BioVentures ProQuest Investments | $90M |
| Series B, 8/09 Nomura Phase4 Ventures New Enterprise Associates HBM BioVentures ProQuest Investments | $30M |
Zosano Pharma is a private pharmaceutical company founded in October 2006 and is focused on creating better products with their innovative drug delivery technology.
Their lead program, parathyroid hormone (PTH) transdermal microprojection delivery system has finalized a Phase 2 clinical trial for treating severe osteoporosis. Zosano’s objective is to discover and develop therapeutic drug candidates which address large unmet medical needs or have a significant potential for commercialization.
